Study of ARC1779 in Patients With Acute Myocardial Infarction Undergoing PCI

A Phase 2 Study of an Aptameric Von Willebrand Factor Antagonist, ARC1779, in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00507338

Acronym

vITAL-1

Enrollment

300

Registered

2007-07-26

Start date

2007-10-31

Completion date

2008-02-29

Last updated

2009-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction

Keywords

percutaneous coronary intervention

Brief summary

ARC1779 is a novel drug being tested in patients undergoing angioplasty and stenting as their primary treatment for heart attack.

Detailed description

Adjunctive anti-thrombotic therapy for PCI of AMI may be improved by incorporation of a novel anti-platelet therapeutic principle, von Willebrand Factor antagonism. ARC1779 is a therapeutic oligonucleotide (aptamer) which blocks the binding of the A1 domain of vWF to the platelet GPIb receptor, and thereby modulates platelet adhesion, activation, and aggregation under the high shear conditions of coronary arterial stenosis and plaque rupture. This study is intended to provide dose-ranging and clinical proof of concept for ARC1779 in a primary PCI population.

Interventions

PROCEDUREPCI

early PCI for NSTEMI; primary PCI for STEMI

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* troponin-positive NSTEMI, with diagnostic symptoms and/or ECG abnormalities present within the preceding 24 hours, and a planned early invasive management strategy * STEMI, with planned primary PCI

Exclusion criteria

* History of bleeding diathesis or evidence of active abnormal bleeding within the previous 30 days * Received treatment with fibrinolytic or GPIIb/IIIa antagonist drugs within the preceding 72 hours * Received anticoagulant therapy with a low molecular weight heparin within the preceding 8 hours * Severe hypertension (systolic blood pressure \>200 mmHg or diastolic blood pressure \>110 mmHg) not adequately controlled on antihypertensive therapy * Major surgery or trauma within the preceding 6 weeks * History of stroke within 30 days or any history of hemorrhagic stroke * End-stage renal disease (ESRD) with dependency on renal dialysis

Design outcomes

Primary

Measure	Time frame
adequacy of reperfusion	48 hours post-PCI

Secondary

Measure	Time frame
bleeding	PCI to hospital discharge

Countries

Russia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026